R

    RAPT (RAPT)

    Official site

    BIOTECHNOLOGY

    $58.02
    +0.00 (+0.00%)

    Last updated: Mar 04, 2026 at 4:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(13/26)
    Avg Surprise
    -127.26%

    Upcoming Estimates

    Period ending Mar 31, 2026
    EPS Consensus$-0.57
    Range$-0.72 - $-0.43
    2 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.73-27.5%
    60d ago$-0.66-14.3%
    30d ago$-0.66-14.3%
    7d ago$-0.67-16.5%
    Current$-0.57
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 26EST
    		-$-0.57---
    Sep 25
    Reported Nov 6
    		$-0.65$-0.11-499.08%Miss-37.2%
    Jun 25
    Reported Aug 7
    		$-0.65$-0.09-622.22%Miss+8.5%
    Mar 25
    Reported May 7
    		$-0.08$-0.14+41.22%Beat+89.9%
    Dec 24
    Reported Mar 5
    		$-1.22$-0.36-243.57%Miss-52.5%
    Sep 24
    Reported Nov 11
    		$-0.47$-0.56+15.39%Beat+42.2%
    Jun 24
    Reported Aug 8
    		$-0.71$-0.72+1.39%Beat-7.6%
    Mar 24
    Reported May 9
    		$-0.79$-0.81+2.47%Beat-3.9%
    Dec 23
    Reported Mar 7
    		$-0.80$-0.86+6.98%Beat-25.0%
    Sep 23
    Reported Nov 13
    		$-0.82$-0.75-9.33%Miss-30.2%
    Jun 23
    Reported Aug 11
    		$-0.66$-0.78+15.38%Beat-6.5%
    Mar 23
    Reported May 11
    		$-0.76$-0.68-11.76%Miss-10.1%
    Dec 22
    Reported Mar 14
    		$-0.64$-0.65+1.54%Beat-4.9%
    Sep 22
    Reported Nov 10
    		$-0.63$-0.67+5.97%Beat+0.0%
    Jun 22
    Reported Aug 11
    		$-0.62$-0.75+17.33%Beat+1.6%
    Mar 22
    Reported May 11
    		$-0.69$-0.68-1.47%Miss-4.5%
    Dec 21
    Reported Mar 10
    		$-0.61$-0.66+7.58%Beat-17.3%
    Sep 21
    Reported Nov 10
    		$-0.63$-0.62-1.61%Miss-5.0%
    Jun 21
    Reported Aug 11
    		$-0.63$-0.67+5.97%Beat-23.5%
    Mar 21
    Reported May 11
    		$-0.66$-0.62-6.45%Miss-17.9%
    Dec 20
    Reported Mar 11
    		$-0.52$-0.59+11.86%Beat+36.6%
    Sep 20
    Reported Nov 16
    		$-0.60$-0.57-5.26%Miss+95.2%
    Jun 20
    Reported Aug 13
    		$-0.51$-0.58+12.07%Beat+67.9%
    Mar 20
    Reported May 14
    		$-0.56$-0.43-30.23%Miss-
    Dec 19
    Reported Mar 30
    		$-0.82$-0.69-18.84%Miss-
    Sep 19
    Reported Dec 11
    		$-12.41$-0.64-1839.06%Miss-
    Jun 19
    Reported Jul 24
    		$-1.59$-0.60-165.00%Miss-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$57.95
    SMA 20$57.85
    SMA 50$48.63
    SMA 200$26.10
    EMA 10$57.90
    EMA 20$56.79
    EMA 50$50.33
    EMA 200$31.47

    MACD

    Line: 2.19Signal: 2.92Hist: -0.73

    ADX

    ADX: 63.5+DI: 48.0-DI: 8.7

    Aroon & PSAR

    Aroon Up100.0
    Aroon DownN/A
    PSAR$57.45

    Bollinger Bands

    Upper Band$58.09
    Lower Band$57.61
    %B Position83%(Upper)
    Band Width0.85

    RSI (14-Day)

    Overbought
    79.2

    Momentum Oscillators

    Stoch %K100.0
    Stoch %D98.6
    Williams %RN/A
    ROC (10d)0.5%
    Momentum0.28
    CCI (20d)109.9
    MFI (14d)68.6

    Volatility Measures

    ATR (14d)$0.48(0.8%)
    StdDev (20d)0.12
    Hist Vol1.8%(Low)

    Volume Flow

    VWAP$58.02
    OBV44.0M
    AD Line9.3B
    CMF (20d)0.043

    Volume Metrics

    Avg Vol (20d)4.3M
    Vol RatioN/A
    VWMA (20d)$57.80

    Pivot Points

    R3$58.02
    R2$58.02
    R1$58.02
    Pivot Point$58.02
    S1$58.02
    S2$58.02
    S3$58.02

    Advanced Oscillators

    TSI58.68
    Ultimate Osc64.6
    KST284.39

    Financial Data

    QuarterSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total Revenue$0$0$0$0$0$0$0$5.29M$0$0$0$641,000
    Cost of Revenue$0$0$0N/A$0$0$0$323,000$0$0$0$730,000
    Gross Profit$0$0$0N/A$0$0$0$4.96M$0$0$0$-89,000
    Operating Expenses$19.37M$19.54M$19.27M$54.47M$19.79M$29.33M$32.52M$33.22M$33.92M$28.36M$31.56M$24.43M
    R&D$12.03M$12.34M$12.04M$46.46M$13.34M$22.64M$24.78M$26.76M$27.02M$21.64M$25.57M$19.45M
    SG&A$7.34M$7.20M$7.22M$8.01M$6.45M$6.69M$7.74M$6.45M$6.90M$6.72M$5.99M$4.98M
    Operating Income$-19,371,000$-19,535,000$-19,265,000$-54,465,000$-19,788,000$-29,330,000$-32,518,000$-33,217,000$-33,919,000$-28,364,000$-31,562,000$-24,431,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-17,580,000$-17,643,000$-17,165,000$-53,249,000$-18,432,000$-27,663,000$-30,521,000$-30,876,000$-31,371,000$-25,280,000$-29,271,000$-22,951,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-17,580,000$-17,643,000$-17,165,000$-53,249,000$-18,432,000$-27,663,000$-30,521,000$-30,876,000$-31,371,000$-25,280,000$-29,271,000$-22,951,000
    EBITDA$-18,110,000$-18,255,000$-17,606,000$-53,492,000$-18,687,000$-28,106,000$-31,190,000$-31,777,000$-32,610,000$-26,518,000$-30,413,000$-24,834,000
    EBIT$-17,580,000$-17,643,000$-17,165,000$-53,249,000$-18,432,000$-27,663,000$-30,521,000$-30,876,000$-31,371,000$-25,280,000$-29,271,000$-24,431,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RAPT

    News

    RAPT Therapeutics (RAPT) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

    RAPT Therapeutics (RAPT) presented at the 43rd Annual J.P. Morgan Healthcare Conference in 2025, highlighting its pipeline expansion with RPT904, a half-life-extended omalizumab biobetter for food allergy and CSU. The company estimates peak U.S. revenue for RPT904 at $4.5 billion for food allergy and $1 billion for CSU, anticipating premium pricing due to improved dosing. Clinical data for RPT904 shows a longer half-life and deeper IgE reduction than omalizumab, with Phase II-B studies for food allergy planned to start in H2 2025.

    Quartr•7/24/26•
    Bullish

    RAPT Therapeutics outlines its immunology pipeline as investors weigh long-term prospects

    RAPT Therapeutics is a clinical-stage biopharmaceutical company focusing on oral small-molecule therapies for immune and inflammatory diseases. The company's pipeline aims to address significant unmet needs in chronic inflammatory and allergic conditions by modulating immune responses. As a US-listed biotech, its valuation is heavily influenced by future clinical data, regulatory outcomes, and broader biotech market sentiment.

    Ad-hoc-news.de•7/3/26•
    Somewhat-Bullish

    RAPT Therapeutics Inc (RAPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

    This article provides a technical analysis of RAPT Therapeutics Inc (RAPT), covering its stock price momentum, support and resistance levels, and insights from various technical indicators and moving averages. The analysis indicates a "Buy" signal based on moving averages and a mixed signal from other indicators. The stock is currently trading between identified resistance and support levels.

    TradingKey•6/19/26•
    Somewhat-Bullish

    RAPT Therapeutics Inc (RAPT) Dividends & Stock Splits: Historical Payouts and Event Timeline

    This article provides an overview of RAPT Therapeutics Inc's (RAPT) dividend history and stock split events. It indicates that RAPT has distributed no dividends over the past five years. The company has a significant merger event scheduled for June 13, 2025, with an 8-to-1 ratio.

    TradingKey•6/18/26•
    Neutral

    RAPT Therapeutics Inc (RAPT) Valuation: PE, PB & Fair Value Analysis

    This article provides a valuation analysis of RAPT Therapeutics Inc (RAPT), indicating its current valuation score is 6.76 within the Biotechnology & Medical Research industry. The company's P/E ratio is -4.99, which is significantly below its recent high and above its recent low. Key valuation metrics such as P/B, P/S, and P/CF are not yet disclosed by the company.

    TradingKey•6/17/26•
    Neutral

    Frequently Asked Questions About RAPT

    Does RAPT pay dividends?
    RAPT (RAPT) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In